Cargando...

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

Bortezomib selectively binds and inhibits the 20S proteasome enzyme’s active sites. This study was conducted to determine the side effects and maximum tolerated dose (MTD) of bortezomib in patients with recurrent malignant glioma. Separate dose escalations were conducted in patients taking or not ta...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Phuphanich, Surasak, Supko, Jeffrey G., Carson, Kathryn A., Grossman, Stuart A., Nabors, L. Burt, Mikkelsen, Tom, Lesser, Glenn, Rosenfeld, Steve, Desideri, Serena, Olson, Jeffrey J.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3811025/
https://ncbi.nlm.nih.gov/pubmed/20213332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0143-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!